INNV (57) OMDA (56) PNTG (56) TDOC (56) ⌘ Pro Terminal →

U.S. Physical Therapy Inc. (USPH) — RQD Stock Rating Cockpit

$86.57 +1.47% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $86.63

U.S. Physical Therapy Inc. (USPH) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.29B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $86.63 (+0.07%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 9.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for USPH)Realized 20D OHLCV Swing Band: ±6.8%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY USPH SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (22% of score)

Altman Z-Score 2.94 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$84.67+1.2% Next Q

Q2 (-2Q)

Grade C$85.71+3.3% Next Q

Q3 (-1Q)

Grade C$88.53-2.2% Next Q

Current

Grade C$86.57+1.1% Hist 90D α

Trajectory: C (56) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the USPH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, USPH faces multiple-compression risk if 32.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 16.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($82.82) or 200D SMA ($76.75) invalidates the momentum regime and cuts Target Base ($88.91) toward Bear Floor ($69.35).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $USPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “USPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

52.330 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.94>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE87% OF RANGE

L: $58$86.57H: $91

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (19% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on USPH

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

11.5% ROIC with 19.2% gross margin and 5.81% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 2.94 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (62)

23/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like USPH

✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (USPH Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

USPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.55%▲ ASCENDING CHANNEL

2026-10-30O $87.26H $87.62L $85.19C $86.57VOL 146.4K

RES: $90.49SUP: $80.93SMA50: $82.82SMA200: $76.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

USPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 USPH Butterfly Map → + Track USPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.2%/yr Implied 5Y Growth

vs. +16.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on USPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for USPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for USPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (USPH)

Health Care Rank #146 of 1016 ⚔️ INNV vs USPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (USPH vs. INNV, OMDA, PNTG, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, U.S. Physical Therapy Inc. (USPH) ranks #146 by composite RQD confidence (64/100, grade C) and #328 by equity capitalization ($1.29B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently leads its immediate peer cohort in composite quantitative strength at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
USPH ACTIVE U.S. Physical Therapy Inc.	C	64/100	32.6x	19.2%	11.5%	+1.47%	$1.29B	Benchmark Subject
INNV InnovAge Holding Corp.	D+	57/100	—	18.0%	-10.2%	+1.54%	$1.26B	/innv-vs-usph →
OMDA Omada Health Inc.	D+	56/100	—	65.7%	-15.7%	+2.45%	$1.20B	/omda-vs-usph →
PNTG The Pennant Group Inc.	D+	56/100	50.2x	—	11.0%	+0.76%	$1.48B	/pntg-vs-usph →
TDOC Teladoc Health Inc.	D+	56/100	—	—	-17.0%	+26.89%	$1.59B	/tdoc-vs-usph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000885978

In its most recent audited fiscal period (FY2025, filed 2025-12-31), U.S. Physical Therapy Inc. (USPH) reported GAAP revenue of $781.0M (+16.3% vs. FY2024 revenue of $671.3M , and +29.1% cumulative change since FY2023) , GAAP net income of $39.6M, operating cash flow of $75.1M, and free cash flow of $75.1M (+0.2% YoY). On the balance sheet, USPH closed FY2025 with $1.20B in total assets against $152.6M in total debt (Altman Z-Score: 2.94, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$781.0M	$39.6M	$75.1M	$75.1M	$1.20B	$152.6M
FY2024 (FY)	2024-12-31	$671.3M	$31.4M	$74.9M	$74.9M	$1.17B	$142.5M
FY2023 (FY)	2023-12-31	$604.8M	$28.2M	$82.0M	$82.0M	—	—

3. USPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is USPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, U.S. Physical Therapy Inc. (NYSE: USPH) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $86.57 (+1.47% 1D, market cap $1.29B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, USPH ranks #146 in composite RQD confidence.

How does USPH compare to INNV and OMDA in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), USPH carries a Roarable C (64/100 RQD), trailing P/E of 32.6x, gross margin of 19.2%, and ROIC of 11.5%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -10.2%, cap $1.26B) and OMDA (Omada Health Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC -15.7%, cap $1.20B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for USPH?

Per USPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000885978), U.S. Physical Therapy Inc. generated $781.0M in revenue (+16.3% YoY), $39.6M in net income, and $75.1M in free cash flow against $1.20B in total assets and $152.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is USPH trading relative to its 50-day, 200-day, and 52-week technical levels?

USPH last traded at $86.57 (+1.47% on volume of 105,198 shares), positioning the stock +4.53% above its 50-day simple moving average ($82.82) and +12.79% above its 200-day simple moving average ($76.75). Across its 52-week range of $58.19 to $90.94, USPH sits at the 86.7% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.8% ($80.68 to $92.46).

USPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell USPH stock right now?

U.S. Physical Therapy Inc. (USPH) currently earns a Roarable Rating of C (Hold — HOLD) with 64/100 RQD Confidence. Solid 19% profit margin (12% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.

What is USPH's 12-month price target and RQD AI Jury consensus?

USPH's 12-month base price target is $88.91 (range $69.35 to $104.91), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: USPH RQD Cockpit USPH 12M Forecast USPH Earnings & Move USPH Dividends & DRIP USPH Insiders & 13F USPH Whale Options USPH Profit Sankey USPH News & Why